Thymosin Alpha-1
aka Thymalfasin (trade name Zadaxin)
Mechanism
Thymosin Alpha-1 (Ta1) is a 28-amino-acid thymic peptide (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN) approved as Zadaxin in 35+ countries for chronic hepatitis B/C and as an immune adjuvant. It is NOT FDA-approved in the US.
Identification
| CAS number | 62304-98-7 |
|---|---|
| Molecular formula | C129H215N33O55 |
| Sequence | SDAAVDTSSEITTKDLKEKKEVVEEAEN |
| Typical dose | 1.6 mg subcutaneous 2–3x/week (clinical standard); research protocols range 1.6–6.4 mg per dose |
| Half-life | ~2–3 hours (subcutaneous; elimination t½ <3 h confirmed by PK study) |
Vendors selling Thymosin Alpha-1
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Peptide Partners | 10 mg | $98.00 | — | 99 |
| Glacier Aminos | 10 mg | $63.99 | — | 99 |
| Moglabs | 5 mg | $36.00 | — | 96 |
| BioLongevity Labs | — | $249.97 | — | 96 |
| BioLongevity Labs | 10 mg | $129.97 | — | 96 |
| Orbitrex Peptides | 10 mg | $79.99 | — | 95 |
| Profound Aminos | 5 mg | $49.00 | — | 95 |
| Ion Peptide | — | $42.00 | — | 95 |
| Licensed Peptides | 5 mg | $359.95 | — | 95 |
| Licensed Peptides | 5 mg | $61.99 | — | 95 |
| Peptide Tech | 5 mg | $28.99 | — | 94 |
| Mile High Compounds | — | $69.99 | — | 94 |
| Forge Performance Co. | 10 mg | $60.00 | — | 94 |
| Amino Club | — | $39.99 | — | 93 |
| Riptide Wellness | 10 mg | $65.00 | — | 92 |
| Hydro Research Peptides | 10 mg | $0.65 | — | 91 |
| Skye Peptides | 10 mg | $79.00 | — | 90 |
| Peptidology | 10 mg | $69.99 | — | 89 |
| Peptide Plugs | 10 mg | $60.00 | — | 89 |
| Verified Peptides | 10 mg | $80.00 | — | 86 |
| EZ Peptides | 10 mg | $58.00 | — | 85 |
| Simple Peptide | 10 mg | $86.00 | — | 85 |
| Peptidegurus | 3 mg | — | — | 84 |
| Peptidegurus | 10 mg | — | — | 84 |
| Reta Peptide | 10 mg | $175.00 | — | 83 |
| Ascension Peptides | 10 mg | $71.00 | — | 83 |
| Cocer Peptides | 10 mg | $185.00 | — | 82 |
| MedGe Peptides | 10 mg | $175.00 | — | 82 |
| Blank Peptides | 10 mg | $75.00 | — | 81 |
| OROS Research | 5 mg | $44.99 | — | 79 |
| Texpeptide | 5 mg | $50.00 | — | 69 |
| Crystal Peptides | 5 mg | $43.99 | — | 66 |
| Qing Li Peptide | — | — | — | 63 |
| Certified Peptides | 10 mg | $78.00 | — | 61 |
| MEI-PEPETIDE | 2 mg | $55.00 | — | 48 |
| DongCheng Peptide | — | — | — | 46 |
| Puratek Peptides | 10 mg | $59.95 | — | 44 |
| Mandy | 5 mg | $80.00 | — | 43 |
| MJT peptides | 5 mg | $106.00 | — | 39 |
| Nextech Labs | 10 mg | $65.00 | — | 24 |
| NG Peptide | 10 mg | $45.00 | — | — |
| Strate Labs | 12.5 mg | $49.95 | — | — |
| Kimera Chems | — | $76.99 | — | — |
| Welli Labs | — | $39.99 | — | — |
| synthesispeptides.io | 10 mg | $74.99 | — | — |
| Alpha Omega | — | $86.00 | — | — |
| Atomik Labz | 10 mg | $65.00 | — | — |
| Biotech Peptides | 10 mg | $130.00 | — | — |
| Bulk Peptides | 5 mg | $200.00 | — | — |
| Core Peptides | 10 mg | $81.00 | — | — |
| Core Peptides | 5 mg | $81.00 | — | — |
| Flawless Compounds | — | — | — | — |
| Genetic Peptide | 5 mg | $65.00 | — | — |
| Genetic Peptide | 15 mg | $65.00 | — | — |
| Lumi Peptides | — | $52.00 | — | — |
| Modern Research Peptides | — | $36.99 | — | — |
| Oasis Labs | 10 mg | $65.00 | — | — |
| Oneday Compounds | 10 mg | $45.49 | — | — |
| Paramount Peptides | 10 mg | $157.25 | — | — |
| Paramount Peptides | 10 mg | $97.75 | — | — |
| Peptide Crafters | 10 mg | $65.00 | — | — |
| Peptira | — | $59.00 | — | — |
| Pepvida Labs | 5 mg | $42.00 | — | — |
| Platinum Lion | 10 mg | $64.99 | — | — |
| Polaris Peptides | 10 mg | $65.00 | — | — |
| S1 Research | 10 mg | $44.00 | — | — |
| Solution Peptides | 10 mg | $65.00 | — | — |
| Soma Peptides | — | $219.00 | — | — |
| Soma Peptides | 16 mg | $124.00 | — | — |
| Southern Aminos | 10 mg | $52.50 | — | — |
| True Peptide | 10 mg | $65.00 | — | — |
| Wellness Peptides | 5 mg | $45.00 | — | — |
| Wellness Peptides | 10 mg | $45.00 | — | — |
| optimasupply.is | — | $65.00 | — | — |
| realpeptides.co | — | $115.00 | — | — |
Research
Chemotherapy induces cancer cell apoptosis and the release of apoptotic bodies (ABs) that are poorly immunogenic or immunosuppressive, creating a major barrier to the success of co-administered or second-line immunotherapies.
source →To report a case of a nasopharyngeal carcinoma patient who developed multisystem immune-related adverse events (irAEs) after treatment with sintilimab (PD-1 inhibitor) in combination with thymosin alpha-1 (Tα1). The patient presents with high fever, rash, interstitial pulmonary edema, and multiple organ failure.
source →The primary objective of this clinical trial is to evaluate the efficacy and safety of spatially fractionated radiotherapy combined with the PraG strategy in the treatment of soft tissue sarcoma (STS). The main questions it aims to answer are: 1.
source →Aging is characterized by immune decline, mainly due to thymic involution-the age-related shrinkage of the thymus gland. This leads to reduced T-cell production, chronic inflammation, and increased susceptibility to age-related diseases.
source →Background The immune-balancing role of thymosin alpha 1 (Tα1) is well-recognized in contexts of immune dysregulation. Within the anti-tumor context, Tα1 demonstrated to act as an immune-enhancer, with potential roles in immunotherapy-based treatments.
source →Background Immune and inflammatory disorders are part of the complex pathophysiological processes that exacerbate severe acute pancreatitis (SAP) and subsequent infection.
source →To validate the efficacy and safety of thymosin α-1 combined with lenvatinib plus sintilimab in the treatment of unresectable hepatocellular carcinoma.
source →Background A considerable proportion (21%) of patients with common variable immunodeficiency (CVID) suffers from depression. These subjects are characterized by reduced naïve T cells and a premature T cell senescence similar to that of patients with major depressive disorder (MDD).
source →Phenotypic drug discovery (PDD) involves screening compounds for their effects on cells, tissues, or whole organisms without necessarily understanding the underlying molecular targets. PDD differs from target-based strategies as it does not require knowledge of a specific drug target or its role in the disease.
source →This systematic review was conducted to assess the curative effect of Thymosin alpha 1 in the acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients.
source →Objective This study aims to assess the safety and efficacy of Thymosin Alpha 1 (Tα1) through a comprehensive narrative review of clinical studies involving over 11 000 human subjects in more than 30 trials.
source →Rationale Triple-negative breast cancer is characterized by a worse prognosis compared with other breast cancer subtypes, especially in the case of pretreated metastatic triple-negative breast cancer (mTNBC).
source →Resistance and toxicity associated with current treatments for human cytomegalovirus (HCMV) infection highlight the need for alternatives and immunotherapy has emerged as a promising strategy.
source →This is a prospective, single-center, single-arm, phase II clinical study.
source →The goal of this research is to learn more about ZADAXIN® (trade name; thymalfasin generic; Ta1 for short) and determine if Ta1 has any benefit in increasing the immune response to the COVID-19 vaccine. Ta1 has been shown to stimulate the immune system to fight infections.
source →This is an open, prospective, multi-center, single-arm phase II clinical study assessing the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin in patients with pMMR/MSS locally advanced middle and low rectal cancer.
source →Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with acute aortic syndrome (AAS). Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with thymosin alpha 1 may be beneficial.
source →The purpose of this study is to evaluate the safety and efficacy of Zadaxin® in the treatment of HIV-positive patients with immune reconstitution disorders.
source →Infected pancreatic necrosis and its related septic complications are the major cause of death in patients with acute pancreatitis, therefore prevention of pancreatic infection is of great clinical value in the treatment of AP.
source →The purpose of this study is to determine whether thymosin alpha 1 is effective on improving monocyte function and has the desired pharmacologic activity for sepsis
source →